Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,580 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Sudden-Onset Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: SAR438544, placebo, r-glucagon; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: CGM and Insulin Pump, Closed-Loop Control System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia

Conditions: Morbid Obesity, Hyperglycemia, Diabetes Mellitus
Interventions: Observational; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes
Interventions: Sleep extension, Fixed Sleep Duration; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 10 Years to 16 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Type 1 Diabetes Mellitus
Interventions: Hyperglycemic clamp; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hypoglycemia
Interventions: Novo Nordisk GlucaGen®, G-Pump™ (glucagon infusion); Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec, insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 23 more

Conditions: Type 1 Diabetes, Type2 Diabetes, Hyperglycemia, Hypoglycemia, Hypoglycemia Unawareness
Interventions: CGM4Home; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Insulin-Dependent Diabetes Mellitus
Interventions: pioglitazone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: IL-2, Rapamycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: New York, New York • Portland, Oregon • Seattle, Washington

Conditions: Type 1 Diabetes
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor, Lymphoma
Interventions: CX-072, ipilimumab, vemurafenib; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more

Conditions: Type 1 Diabetes
Interventions: Vitamin D, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 4 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 5 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Solid Tumor, Unresectable or Metastatic Melanoma
Interventions: CX-072, Ipilimumab; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more

Conditions: Type 1 Diabetes
Interventions: Medtronic MiniMed Closed Loop (CL) System, Snacking; Device · Other
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 44 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes, Type 1 Diabetes
Interventions: Unified protocol for cognitive behavioral therapy (UP-CBT), Continuous Glucose Monitoring (CGM); Behavioral · Device
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • The Bronx, New York

Conditions: Type 1 Diabetes
Interventions: interoperable Artificial Pancreas System (iAPS), Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS); Device · Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Santa Barbara, California • Stanford, California • Boston, Massachusetts + 2 more

Conditions: Type 1 Diabetes, Obesity
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York

Conditions: Type 1 Diabetes
Interventions: Mylan's insulin glargine, Lantus®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 72
States / cities: Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Dapagliflozin 5mg, Placebo; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 12 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Group education sessions; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 13 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 1
Interventions: Teens-Connect, Planet D; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: New Haven, Connecticut • Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus Type 1
Interventions: Allogeneic Pancreatic Endocrine Cell Clusters; Biological
Lead sponsor: Seraxis; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Search by objective public record fields.

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation

Characteristics of Dendritic Cells Before and After Gastric Banding

Sleep Intervention for Youth With Type 1 Diabetes

Using Wearable Sensors To Understand Low Blood Sugar in Type 1 Diabetes

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

Continuous Glucose Monitoring Initiation at Hospital Discharge

Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

Proleukin and Rapamune in Type 1 Diabetes

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes

Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop

Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression

The International Diabetes Closed Loop (iDCL) Trial: Protocol 4

PET Scan Imaging of Beta Cell Mass

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

High Risk Youth With Poorly-controlled Diabetes

Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes

A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia